A Neck Injection Is Showing Real Promise for People With PTSD

Imagine carrying a smoke alarm inside the body that goes off every few minutes — even when there is no fire, no danger, and nowhere near any smoke. The alarm cannot be switched off. It just keeps screaming, making it impossible to sleep, to relax, to feel safe, to trust other people, to live normally. This is roughly what happens inside the body of someone with post-traumatic stress disorder. The nervous system's alarm system got stuck in the "on" position after a terrifying experience — and no amount of telling it to calm down makes it quiet. Now a new scientific review published in Autonomic Neuroscience has found that a precise injection of numbing medicine into a cluster of nerves in the neck can physically reach in and turn that alarm down — producing measurable, clinically significant improvements in PTSD symptoms.

The Problem With How We Treat PTSD Today

Post-traumatic stress disorder is one of the most common and most under-treated mental health conditions in the world. Between 5% and 12% of people will experience it at some point in their lives, with a lifetime prevalence of close to 9%. It is most common after combat, sexual violence, serious accidents, natural disasters, and childhood trauma — but it can follow any terrifying event. Sufferers relive the experience through flashbacks and nightmares, feel constantly on edge and hyperalert, avoid anything that reminds them of what happened, and often feel detached from the world and the people around them. The two main treatments available today are therapy — particularly cognitive behavioural therapy and exposure therapy — and medications, mainly antidepressants called SSRIs and SNRIs. Both work for some people. But neither works reliably enough. Drug treatment only succeeds in about 60% of cases, often takes 4 to 8 weeks to start making any difference, and comes with side effects — nausea, weight changes, sexual dysfunction — that cause 30% to 50% of patients to quit before the treatment has a chance to work. Therapy can be more effective, but it takes time, requires a willing and trained therapist, and many patients — especially those with military trauma or cultural stigma around mental illness — will not pursue it. The result is that only 45% to 65% of people get meaningful relief from the first treatment they try. This is why researchers have been searching urgently for something different.

What Exactly Is a Stellate Ganglion Block?

Deep inside the lower neck, just in front of the seventh cervical vertebra — the last big bone one can feel at the base of the neck — sits a small cluster of nerve cells called the stellate ganglion. It is shaped roughly like a star, which is where its name comes from (stellate means star-shaped in Latin). This cluster is part of the body's sympathetic nervous system — the "fight, flight, or freeze" network that floods the body with stress hormones and alertness signals when danger is detected. When someone develops PTSD, this system — and the wider sympathetic network it belongs to — gets locked into a state of chronic overactivity. The brain receives a constant stream of alarm signals even when everything around the person is perfectly safe. A stellate ganglion block (SGB) involves guiding a very thin needle to this nerve cluster using an ultrasound camera for precision, then injecting a small amount of local anaesthetic. The same type of numbing medicine a dentist uses to numb a tooth. For a period of hours to potentially weeks, the nerve signals flowing through the stellate ganglion are quieted. The body's alarm volume gets turned down. Doctors have been performing SGB for decades to treat chronic pain, irregular heartbeat, and hot flashes. Using it for PTSD is a newer idea — but the biology made sense from the beginning.

How Does a Neck Injection Calm PTSD in the Brain?

The mechanism behind why SGB helps PTSD is still being studied, but researchers have identified several likely pathways. The most important involves a protein called nerve growth factor (NGF). In people with PTSD, the overactive sympathetic nervous system appears to drive excessive production of NGF in regions of the brain involved in fear and stress responses. This extra NGF causes the stress-signalling circuits to become overgrown and over-connected — like a weed that has been given fertiliser. By temporarily blocking the stellate ganglion, the injection interrupts the signals that drive NGF overproduction, allowing those overgrown stress circuits to partially reset. A second pathway involves the hypothalamic-pituitary-adrenal axis — often shortened to the HPA axis — which is the body's central stress hormone control system. By calming the nerve signals coming through the stellate ganglion, the SGB may reduce the overproduction of cortisol and other stress hormones that keep PTSD symptoms running at full power. The result, in simple terms, is a temporary but meaningful quieting of the stuck alarm — giving the brain a window of reduced hyperarousal during which it can begin to recover, process memories more calmly, and respond better to therapy.

What the New Review of Clinical Trials Found

The research team at Kunming Medical University in China conducted a thorough systematic search of seven major medical databases — PubMed, EMBASE, Web of Science, the Cochrane Library, and three Chinese research databases — looking for every published clinical trial that tested stellate ganglion block as a treatment for PTSD. From 394 initial records, they identified three eligible studies involving 208 patients in total, including two randomised controlled trials and one case-control trial. A randomised controlled trial is the gold standard of medical research — the same method used to approve new drugs. The combined result of the analysis was clear. Patients who received SGB showed a significant reduction in their PTSD symptom score on the Clinician-Administered PTSD Scale (CAPS) — the most widely used standardised measure of PTSD severity. The pooled mean difference was minus 6.24 points (with a 95% confidence interval of minus 10.71 to minus 1.78, P = 0.006). A drop of more than 6 points on the CAPS scale is considered clinically meaningful — the kind of change that translates into a person sleeping better, being less hypervigilant, having fewer flashbacks, and feeling more capable of everyday life.

How SGB Compares to Standard Treatments

The comparison between SGB and standard PTSD treatments reveals some striking differences — particularly for patients who struggle with current options.

Importantly, SGB is not proposed as a replacement for therapy or medication. The researchers suggest it may work best as a complementary tool — used alongside therapy to lower the body's hyperarousal enough that the patient can engage more effectively with the psychological work. Some clinical programmes are already using this combination approach, particularly for military veterans and first responders who have not responded to standard treatment.

Who Could Benefit and What Comes Next

The researchers are cautious about over-claiming their results. The meta-analysis included only three studies and 208 patients — a small number by the standards of pharmaceutical drug approval. The studies came from the United States and China, and the patient populations differed in important ways. More large, well-designed randomised controlled trials are needed — testing more patients, over longer time periods, with consistent outcome measures — before SGB can be considered a confirmed standard treatment for PTSD. That said, the existing evidence is promising enough that the US Department of Veterans Affairs has already begun exploring SGB as an option for veterans with treatment-resistant PTSD. The procedure is available at specialist pain management and anaesthesiology centres in multiple countries. People who might particularly benefit include those who have failed two or more standard treatments, those who cannot tolerate PTSD medications due to side effects, and those whose hyperarousal symptoms (constant alertness, inability to sleep, extreme startle responses) are the most prominent feature of their condition. For anyone who has been living with the body's alarm stuck in the on position, and for whom the usual remedies have not worked — this injection may represent something genuinely new: a way to reach physically into the nervous system and help the alarm finally, quietly, turn itself off.

• Clinically significant result: SGB reduced PTSD symptom scores by more than 6 points on the gold-standard CAPS scale — a meaningful improvement in real-world symptoms.
• Targets the root cause: Rather than masking symptoms, SGB physically quiets the overactive sympathetic nerve network that drives PTSD's constant alarm state.
• Fast acting: Effects are reported within hours to days, compared to 4–8 weeks for medications.
• More evidence needed: The review covered only 208 patients in 3 trials. Larger randomised trials are urgently needed to confirm and expand these findings.

"The SGB treatment demonstrates efficacy in alleviating symptoms in people with PTSD. Nonetheless, the limited quantity of randomized controlled trials included necessitates a more extensive collection of high-quality randomized controlled trials to substantiate this result further." — Yang et al., Autonomic Neuroscience, Vol. 262, 2025.